ArticleFrontiers in pharmacology2021
Extract From
Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 20 citations in OpenAlex.
- Harnessing network pharmacology in drug discovery: an integrated approach.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Network pharmacology predicts targets and pathways of herbal components for the treatment of pneumonia: A review.Medicine · 2025Review
- Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria.Frontiers in immunology · 2025Review
- Regulatory T cells in lung disease and transplantation.Bioscience reports · 2023Review
- Insights into Metabolic Engineering of Bioactive Molecules inCurrent genomics · 2023Review
- Gut microbiota and transcriptome profiling revealed the protective effect of aqueous extract ofCurrent research in food science · 2023Article
- Multi-omics analyses revealed key factors involved in fluorescent carbon-dots-regulated secondary metabolism in Tetrastigma hemsleyanum.Journal of nanobiotechnology · 2022Article
- Gut Microbiota Protected AgainstFrontiers in cellular and infection microbiology · 2022Article
- Cyclin-Dependent Kinase 6 Identified as the Target Protein in the Antitumor Activity ofFrontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.